Tarsus Pharmaceuticals (TARS) Financials: History & Chart

Tarsus Pharmaceuticals, Inc.(TARS)

Biotechnology · Irvine, CA

$74.11-0.34 (-0.46%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Irvine, CA

370 employees

www.tarsusrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bobak R. Azamian

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	606.33M	173.91M	162.05M	151.67M	118.70M	102.66M	78.33M	66.41M	48.12M
Cost of Goods Sold	57.03M	12.11M	9.40M	10.93M	24.59M	6.24M	5.21M	4.93M	3.24M
Gross Profit	549.30M	161.80M	152.66M	140.74M	94.10M	96.42M	73.12M	61.48M	44.88M
Gross Profit Margin	90.6%	93.0%	94.2%	92.8%	79.3%	93.9%	93.3%	92.6%	93.3%
Total Operating Expenses	597.84M	181.71M	158.78M	148.72M	108.63M	118.61M	99.40M	85.90M	70.04M
Research & Development	87.68M	31.01M	22.35M	18.04M	16.28M	15.59M	14.41M	16.87M	12.13M
Selling, General & Administrative	526.44M	150.70M	136.43M	130.68M	108.63M	103.01M	85.00M	69.03M	57.91M
Operating Income (EBIT)	-48.53M	-19.91M	-6.12M	-7.98M	-14.53M	-22.18M	-26.28M	-24.42M	-25.16M
Operating Margin	-8.0%	-11.4%	-3.8%	-5.3%	-12.2%	-21.6%	-33.5%	-36.8%	-52.3%
Income Before Tax (EBT)	-44.05M	-15.84M	-9.32M	-6.31M	-12.59M	-20.34M	-25.12M	-23.11M	-23.42M
Interest Income	15.48M	3.70M	3.72M	3.95M	4.11M	4.23M	3.45M	3.65M	4.12M
Interest Expense	8.61M	2.16M	2.13M	2.21M	2.12M	2.09M	2.07M	2.17M	2.32M
Other Income/Expense	4.48M	4.07M	-3.20M	1.66M	1.94M	1.84M	1.16M	1.31M	1.74M
Net Income	-46.48M	-18.55M	-6.97M	-8.37M	-12.59M	-20.34M	-25.12M	-23.11M	-23.42M
Income Tax Expense	2.42M	2.72M	-2.35M	2.06M	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-7.7%	-10.7%	-4.3%	-5.5%	-10.6%	-19.8%	-32.1%	-34.8%	-48.7%
EBITDA	-46.20M	-18.91M	-5.68M	-7.53M	-14.07M	-21.73M	-25.82M	-23.99M	-24.86M
EBITDA Margin	-7.6%	-10.9%	-3.5%	-5.0%	-11.9%	-21.2%	-33.0%	-36.1%	-51.7%
Depreciation & Amortization	2.34M	1.00M	437K	443K	460K	453K	460K	432K	300K
EPS Basic	-1.09	-0.43	-0.16	-0.20	-0.30	-0.48	-0.64	-0.60	-0.61
EPS Diluted	-1.09	-0.43	-0.16	-0.20	-0.30	-0.48	-0.64	-0.60	-0.61
Weighted Average Basic Shares	43.39M	43.39M	42.96M	42.78M	42.61M	42.36M	39.35M	38.56M	38.38M
Weighted Average Diluted Shares	43.39M	43.39M	42.96M	42.78M	42.61M	42.36M	39.35M	38.56M	38.38M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	451.36M	182.95M	17.45M	25.82M	57.03M	0.00	0.00	0.00
Cost of Goods Sold	30.68M	12.83M	1.59M	955K	2.08M	246K	74K	1K
Gross Profit	420.68M	170.13M	15.85M	24.86M	54.95M	-246K	-74K	-1K
Gross Profit Margin	93.2%	93.0%	90.9%	96.3%	96.4%	N/A	N/A	N/A
Total Operating Expenses	491.64M	290.70M	159.01M	87.57M	67.11M	26.74M	4.22M	1.35M
Research & Development	64.32M	53.39M	50.31M	42.62M	41.71M	18.83M	3.16M	901K
Selling, General & Administrative	427.32M	237.31M	108.70M	44.95M	25.40M	7.93M	1.06M	448K
Operating Income (EBIT)	-70.97M	-120.57M	-143.16M	-62.71M	-12.16M	-26.98M	-4.30M	-1.35M
Operating Margin	-15.7%	-65.9%	-820.5%	-242.9%	-21.3%	N/A	N/A	N/A
Income Before Tax (EBT)	-64.36M	-115.55M	-135.89M	-62.09M	-13.77M	-26.81M	-4.67M	-1.32M
Interest Income	15.75M	15.01M	10.34M	3.50M	36K	188K	40K	N/A
Interest Expense	8.94M	7.45M	3.23M	2.06M	N/A	188K	40K	N/A
Other Income/Expense	6.61M	5.01M	7.26M	617K	-1.61M	173K	-371K	32K
Net Income	-66.42M	-115.55M	-135.89M	-62.09M	-13.83M	-26.81M	-4.67M	-1.32M
Income Tax Expense	2.06M	0.00	0.00	-4K	55K	1K	1K	1K
Net Profit Margin	-14.7%	-63.2%	-778.9%	-240.5%	-24.2%	N/A	N/A	N/A
EBITDA	-69.15M	-119.34M	-142.28M	-62.39M	-11.85M	-26.74M	-4.22M	-1.35M
EBITDA Margin	-15.3%	-65.2%	-815.5%	-241.7%	-20.8%	N/A	N/A	N/A
Depreciation & Amortization	1.82M	1.23M	877K	326K	312K	246K	74K	1K
EPS Basic	-1.59	-3.07	-4.62	-2.52	-0.67	-1.32	-0.24	-0.31
EPS Diluted	-1.59	-3.07	-4.62	-2.52	-0.67	-1.32	-0.24	-0.31
Weighted Average Basic Shares	41.78M	37.60M	29.38M	24.62M	20.55M	20.32M	19.51M	4.29M
Weighted Average Diluted Shares	41.78M	37.60M	29.38M	24.62M	20.55M	20.32M	19.51M	4.29M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.